> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Ultragenyx Sells Priority Review Voucher for $210 million
- URL: https://www.fdaweb.com/ultragenyx-sells-priority-review-voucher-for-210-million/
- Published: 2026-10-08T19:25:48.000Z
- Updated: 2026-10-08T19:25:48.000Z
- Author: David McFarland
- Tags: Biologics

Ultragenyx Pharmaceutical has agreed to sell its Rare Pediatric Disease Priority Review Voucher to an undisclosed buyer for $210 million. FDA awarded the voucher in August upon approval of Genglycos (pariglasgene brecaparvovec-opnr), also known as DTX401, for use in adult and pediatric patients eight years and older with glycogen storage disease Type Ia.

Under the terms of a 2018 patent license agreement, 20% of the gross proceeds from the voucher’s sale will be payable to NIH.